Literature DB >> 7236068

Central dazzle. A thalamic syndrome?

J L Cummings, J W Gittinger.   

Abstract

A patient who experienced painless intolerance to light (dazzle) three months after a right posterior cerebral artery occlusion was shown by computerized tomography to have right occipital and right thalamic infarctions. His symptoms improved with amitriptyline hydrochloride and perphenazine therapy. The sensitivity to light, delayed onset, response to therapy, and presence of a thalamic lesion are analogous to the thalamic pain syndrome and suggest that central dazzle is a variant of the thalamic syndrome.

Entities:  

Mesh:

Year:  1981        PMID: 7236068     DOI: 10.1001/archneur.1981.00510060074014

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  7 in total

Review 1.  Neurovisual rehabilitation: recent developments and future directions.

Authors:  G Kerkhoff
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-06       Impact factor: 10.154

2.  Lack of photophobia associated with bilateral ventral occipital lesion.

Authors:  Hiroshi Horiguchi; Hiroyuki Kubo; Satoshi Nakadomari
Journal:  Jpn J Ophthalmol       Date:  2011-05-11       Impact factor: 2.447

Review 3.  Shedding light on photophobia.

Authors:  Kathleen B Digre; K C Brennan
Journal:  J Neuroophthalmol       Date:  2012-03       Impact factor: 3.042

4.  Current understanding of photophobia, visual networks and headaches.

Authors:  Rodrigo Noseda; David Copenhagen; Rami Burstein
Journal:  Cephalalgia       Date:  2018-06-25       Impact factor: 6.292

5.  Development of a quantitative method to measure vision in children with chronic cortical visual impairment.

Authors:  W V Good
Journal:  Trans Am Ophthalmol Soc       Date:  2001

Review 6.  Photophobia: When Light Hurts, a Review.

Authors:  Abdul Albilali; Esma Dilli
Journal:  Curr Neurol Neurosci Rep       Date:  2018-07-30       Impact factor: 5.081

Review 7.  Visual function in preterm infants: visualizing the brain to improve prognosis.

Authors:  Vann Chau; Margot J Taylor; Steven P Miller
Journal:  Doc Ophthalmol       Date:  2013-06-13       Impact factor: 2.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.